Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilacidin (Primary)
  • Indications COVID-19 respiratory infection
  • Focus Therapeutic Use
  • Sponsors Innovation Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2022 Results presented in an Innovation Pharmaceuticals Media Release.
    • 25 Oct 2021 According to an Innovation Pharmaceuticals media release, the company anticipates reporting topline results from this trial in the week of November 8th .
    • 13 Aug 2021 According to an Innovation Pharmaceuticals media release, topline results from this trial are anticipated to be available one week after database lock, with full analysis to follow.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top